Vitamin D activities and metabolic bone disease

Clinica Chimica Acta

Volumn 425, Issue , 2013, Pages 148-152

  Ryan, Jackson W ^a,b   Anderson, Paul H ^a,b   Turner, Andrew G ^a,b   Morris, Howard A ^a,b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b HANSON INSTITUTE   (Australia)

Author keywords

25 Hydroxyvitamin D 1 hydroxylase (CYP27B1); Dietary calcium; Fracture; Osteomalacia; Osteoporosis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; VITAMIN D; VITAMIN D RECEPTOR;

BONE DENSITY; BONE TURNOVER; CALCIUM INTAKE; DIET SUPPLEMENTATION; FRACTURE; GENE EXPRESSION REGULATION; GENE MUTATION; HIP FRACTURE; HUMAN; METABOLIC BONE DISEASE; NONHUMAN; OSTEOMALACIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RICKETS; RISK FACTOR; RISK REDUCTION; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

25-HYDROXYVITAMIN D 1Α-HYDROXYLASE (CYP27B1); DIETARY CALCIUM; FRACTURE; OSTEOMALACIA; OSTEOPOROSIS; VITAMIN D;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; BONE AND BONES; BONE DENSITY; CALCIFICATION, PHYSIOLOGIC; CALCIUM; CHILD; GENE EXPRESSION REGULATION; HUMANS; OSTEOMALACIA; OSTEOPOROSIS; PHOSPHATES; RECEPTORS, CALCITRIOL; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84882966635     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.07.024     Document Type: Review

References (53)

1. Morris H.A., Vitamin D. 2013: where do the hypebole end and the facts begin?. Nutr Diet 2013, 70:5-6.
2. Bischoff-Ferrari H.A., Willett W.C., Orav E.J., et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012, 367:40-49.
3. Prentice R.L., Pettinger M.B., Jackson R.D., et al. Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporos Int 2013, 24:567-580.
4. Kream B.E., Yamada S., Schnoes H.K., DeLuca H.F. Specific cytosol-binding protein for 1,25-dihydroxyvitamin D3 in rat intestine. J Biol Chem 1977, 252:4501-4505.
5. Howard G.A., Turner R.T., Sherrard D.J., Baylink D.J. Human bone cells in culture metabolize 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. J Biol Chem 1981, 256:7738-7740.
6. Anderson P.H., O'Loughlin P.D., May B.K., Morris H.A. Modulation of CYP27B1 and CYP24 mRNA expression in bone is independent of circulating 1,25(OH)2D3 levels. Bone 2005, 36:654-662.
7. Kogawa M., Anderson P.H., Findlay D.M., Morris H.A., Atkins G.J. The metabolism of 25-(OH)vitamin D3 by osteoclasts and their precursors regulates the differentiation of osteoclasts. J Steroid Biochem Mol Biol 2010, 121:277-280.
8. Omdahl J.L., Morris H.A., May B.K. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 2002, 22:139-166.
9. Mellanby E. An experimental investigation on rickets. Lancet 1919, 193:407-412.
10. Holick M.F. Vitamin D, deficiency. N Engl J Med 2007, 357:266-281.
11. Ross A.C., Taylor C.L., A.L Y., Del Valle H.B. Committee to Review Dietary Reference Intakes for Vitamin D and Calcium 2011, Institute of Medicine National Acadamies Press, Washington DC.
12. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:1911-1930.
13. DeLuca H.F., Schnoes H.K. Metabolism and mechanism of action of vitamin D. Annu Rev Biochem 1976, 45:631-666.
14. Hendrix I., Anderson P.H., Omdahl J.L., May B.K., Morris H.A. Response of the 5'-flanking region of the human 25-hydroxyvitamin D 1alpha-hydroxylase gene to physiological stimuli using a transgenic mouse model. J Mol Endocrinol 2005, 34:237-245.
15. Need A.G., O'Loughlin P.D., Morris H.A., Coates P.S., Horowitz M., Nordin B.E. Vitamin D metabolites and calcium absorption in severe vitamin D deficiency. J Bone Miner Res 2008, 23:1859-1863.
16. Anderson P.H., Sawyer R.K., Moore A.J., May B.K., O'Loughlin P.D., Morris H.A. Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model. J Bone Miner Res 2008, 23:1789-1797.
17. Morris H.A., Morrison G.W., Burr M., Thomas D.W., Nordin B.E. Vitamin D and femoral neck fractures in elderly South Australian women. Med J Aust 1984, 140:519-521.
18. Lai J.K., Lucas R.M., Clements M.S., Roddam A.W., Banks E. Hip fracture risk in relation to vitamin D supplementation and serum 25-hydroxyvitamin D levels: a systematic review and meta-analysis of randomised controlled trials and observational studies. BMC Public Health 2010, 10:331.
19. Lips P., van Ginkel F.C., Jongen M.J., Rubertus F., van der Vijgh W.J., Netelenbos J.C. Determinants of vitamin D status in patients with hip fracture and in elderly control subjects. Am J Clin Nutr 1987, 46:1005-1010.
20. Chapuy M.C., Arlot M.E., Duboeuf F., et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992, 327:1637-1642.
21. Chapuy M.C., Pamphile R., Paris E., et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002, 13:257-264.
22. Jackson R.D., LaCroix A.Z., Gass M., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006, 354:669-683.
23. Avenell A., Gillespie W.J., Gillespie L.D., OC D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009, 15.
24. Kim C.J., Kaplan L.E., Perwad F., et al. Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency. J Clin Endocrinol Metab 2007, 92:3177-3182.
25. Huang D.C., Papavasiliou V., Rhim J.S., Horst R.L., Kremer R. Targeted disruption of the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in ras-transformed keratinocytes demonstrates that locally produced 1alpha,25-dihydroxyvitamin D3 suppresses growth and induces differentiation in an autocrine fashion. Mol Cancer Res 2002, 1:56-67.
26. Atkins G.J., Anderson P.H., Findlay D.M., et al. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone 2007, 40:1517-1528.
27. van Driel M., Pols H.A., van Leeuwen J.P. Osteoblast differentiation and control by vitamin D and vitamin D metabolites. Curr Pharm Des 2004, 10:2535-2555.
28. Anderson P.H., Atkins G.J., Findlay D.M., et al. RNAi-mediated silencing of CYP27B1 abolishes 1,25(OH)2D3 synthesis and reduces osteocalcin and CYP24 mRNA expression in human osteosarcoma (HOS) cells. J Steroid Biochem Mol Biol 2007, 103:601-605.
29. Geng S., Zhou S., Glowacki J. Effects of 25-hydroxyvitamin D(3) on proliferation and osteoblast differentiation of human marrow stromal cells require CYP27B1/1alpha-hydroxylase. J Bone Miner Res 2011, 26:1145-1153.
30. Anderson P.H., O'Loughlin P.D., May B.K., Morris H.A. Quantification of mRNA for the vitamin D metabolizing enzymes CYP27B1 and CYP24 and vitamin D receptor in kidney using real-time reverse transcriptase-polymerase chain reaction. J Mol Endocrinol 2003, 31:123-132.
31. Anderson P.H., O'Loughlin P.D., May B.K., Morris H.A. Determinants of circulating 1,25-dihydroxyvitamin D3 levels: the role of renal synthesis and catabolism of vitamin D. J Steroid Biochem Mol Biol 2004, 89-90:111-113.
32. Kogawa M., Findlay D.M., Anderson P.H., et al. Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption. Endocrinology 2010, 151:4613-4625.
33. Kogawa M., Findlay D.M., Anderson P.H., Atkins G.J. Modulation of osteoclastic migration by metabolism of 25(OH)-vitamin D(3). J Steroid Biochem Mol Biol 2013, 136:59-61.
34. Dardenne O., Prud'homme J., Arabian A., Glorieux F.H., St-Arnaud R. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 2001, 142:3135-3141.
35. Dardenne O., Prud'homme J., Hacking S.A., Glorieux F.H., St-Arnaud R. Correction of the abnormal mineral ion homeostasis with a high-calcium, high-phosphorus, high-lactose diet rescues the PDDR phenotype of mice deficient for the 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1). Bone 2003, 32:332-340.
36. Turner A.G., O'Loughlin P.D., Kogawa M., Atkins G.J., Anderson P.H., Morris H.A. Increased bone volume in the bone-specific CYP27B1 transgenic mouse. Osteoporos Int 2011, 22:S590-S591.
37. Anderson P.H., Turner A.G., Sawyer R.K., O'Loughlin P.D., Atkins G.J., Morris H.A. Enhanced vitamin D synthesis in osteoblasts protects against age-related bone loss. J Bone Miner Res 2011, S151.
38. Rosen J.F., Fleischman A.R., Finberg L., Hamstra A., DeLuca H.F. Rickets with alopecia: an inborn error of vitamin D metabolism. J Pediatr 1979, 94:729-735.
39. Liberman U.A., Samuel R., Halabe A., et al. End-organ resistance to 1,25-dihydroxycholecalciferol. Lancet 1980, 1:504-506.
40. Brooks M.H., Bell N.H., Love L., et al. Vitamin-D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D. N Engl J Med 1978, 298:996-999.
41. Li Y.C., Pirro A.E., Amling M., et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 1997, 94:9831-9835.
42. Yoshizawa T., Handa Y., Uematsu Y., et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997, 16:391-396.
43. Amling M., Priemel M., Holzmann T., et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 1999, 140:4982-4987.
44. Li Y., Amling M., Pirro A.E., et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 1998, 139.
45. Lieben L., Masuyama R., Torrekens S., et al. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest 2012, 122:1803-1815.
46. Xue Y., Fleet J.C. Intestinal vitamin D receptor is required for normal calcium and bone metabolism in mice. Gastroenterology 2009, 136:1317-1327. (e1311-1312).
47. Erben R.G., Soegiarto D.W., Weber K., et al. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol Endocrinol 2002, 16:1524-1537.
48. Cochran M., Coates P.T., Morris H.A. The effect of calcitriol on fasting urine calcium loss and renal tubular reabsorption of calcium in patients with mild renal failure-actions of a permissive hormone. Clin Nephrol 2005, 64:98-102.
49. Hoenderop J.G., van Leeuwen J.P., van der Eerden B.C., et al. Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 2003, 112:1906-1914.
50. Panda D.K., Miao D., Bolivar I., et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004, 279:16754-16766.
51. Yamamoto Y., Yoshizawa T., Fukuda T., et al. Vitamin D receptor in osteoblasts is a negative regulator of bone mass control. Endocrinology 2013, 154:1008-1020.
52. Gardiner E.M., Baldock P.A., Thomas G.P., et al. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage. FASEB J 2000, 14:1908-1916.
53. Misof B.M., Roschger P., Tesch W., et al. Targeted overexpression of vitamin D receptor in osteoblasts increases calcium concentration without affecting structural properties of bone mineral crystals. Calcif Tissue Int 2003, 73:251-257.